vTv Therapeutics Inc. Announces Pricing of Initial Public Offering
July 29 2015 - 9:47PM
Business Wire
vTv Therapeutics Inc. (the “Company”) (Nasdaq:VTVT) announced
today the pricing of its initial public offering of 7,812,500
shares of its Class A common stock at a price to the public of
$15.00 per share. All of the shares are being offered by the
Company. In addition, the Company has granted the underwriters an
option to purchase up to an additional 1,171,875 shares of Class A
common stock. The shares of Class A common stock are expected to
begin trading on the Nasdaq Global Market on July 30, 2015, under
the symbol “VTVT.”
The Company intends to use the net proceeds of the offering to
fund the STEADFAST Study (its ongoing Phase 3 trial of azeliragon,
a drug candidate for the treatment of Alzheimer's disease), further
clinical development of its other drug candidates (including two
drug candidates for the treatment of type 2 diabetes that are in or
commencing Phase 2 studies) and for working capital and other
general corporate purposes.
Piper Jaffray & Co. and Stifel are acting as joint
book-running managers for the offering. In addition, Canaccord
Genuity Inc. and Janney Montgomery Scott LLC are acting as
co-managers for the offering.
The offering is being made only by means of a prospectus. A copy
of the final prospectus related to the offering may be obtained,
when available, from Piper Jaffray & Co., Attention: Prospectus
Department, 800 Nicollet Mall, J12S03, Minneapolis, MN 55402, by
telephone at (800) 747-3924, or by email at prospectus@pjc.com; or
Stifel, Nicolaus & Company, Incorporated, One Montgomery
Street, Suite 3700, San Francisco, CA 94104, Attention: Syndicate,
by telephone at (415) 364-2720 or by email at
syndprospectus@stifel.com.
A registration statement relating to these securities has been
filed with, and declared effective by, the Securities and Exchange
Commission. This press release shall not constitute an offer to
sell or the solicitation of an offer to buy, nor shall there be any
sale of these securities in any state or jurisdiction in which such
offer, solicitation or sale would be unlawful prior to registration
or qualification under the securities laws of any such state or
jurisdiction.
About vTv Therapeutics
vTv Therapeutics Inc. is a clinical-stage biopharmaceutical
company engaged in the discovery and development of orally
administered small molecule drug candidates to fill significant
unmet medical needs. vTv has a pipeline of clinical drug candidates
led by programs for the treatment of Alzheimer’s disease and type 2
diabetes as well as treatment of inflammatory disorders and the
prevention of muscle weakness.
Forward-Looking Statements
This press release contains forward-looking statements. You
should not place undue reliance on those statements because they
are subject to numerous uncertainties and factors relating to the
Company's operations and business environment, all of which are
difficult to predict and many of which are beyond the Company's
control. Forward-looking statements include information concerning
the Company's possible or assumed future results of operations,
including descriptions of the Company's business strategy. These
statements often include words such as “may,” “will,” “should,”
“believe,” “expect,” “anticipate,” “intend,” “plan,” “estimate” or
similar expressions. These statements are based on assumptions that
the Company has made in light of its experience in the industry as
well as its perceptions of historical trends, current conditions,
expected future developments and other factors it believes are
appropriate under the circumstances. Although the Company believes
that these forward-looking statements are based on reasonable
assumptions, we can give no assurance they will prove to be
correct. Therefore, you should be aware that many factors could
affect the Company's actual financial results or results of
operations and could cause actual results to differ materially from
those in the forward-looking statements. These factors are
discussed in the “Risk Factors” and “Management’s Discussion and
Analysis of Financial Condition and Results of Operations” sections
and elsewhere in the Company's registration statement.
You should keep in mind that any forward-looking statement made
by the Company herein, or elsewhere, speaks only as of the date on
which made. New risks and uncertainties come up from time to time,
and it is impossible for the Company to predict these events or how
they may affect it. The Company has no obligation to update any
forward-looking statements after the date hereof, except as
required by federal securities laws.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20150729006885/en/
InvestorsThe Trout GroupMarc Panoff,
646-378-2958mpanoff@troutgroup.comorMediaBMC
CommunicationsBrad Miles,
646-513-3125bmiles@bmccommunications.com
vTv Therapeutics (NASDAQ:VTVT)
Historical Stock Chart
From Mar 2024 to Apr 2024
vTv Therapeutics (NASDAQ:VTVT)
Historical Stock Chart
From Apr 2023 to Apr 2024